SCHEMBL4693209

SCHEMBL4693209

O=C1c2ccccc2C(=O)N1C1CCN(c2cncc(Cl)n2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
CYP1A2 P05177 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
CYP3A4 P08684 1/20 0.47
HTR1A P08908 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
CYP2C19 P33261 1/20 0.47
HSD17B10 Q99714 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.44
HTR3E A5X5Y0 1/20 0.42
HTR3B O95264 1/20 0.42
CYP2D6 P10635 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4789263 0.82 ADRA1D (0.40) CYP1A2KDM4ECYP3A4CYP2C9CYP2C19
SCHEMBL4694061 0.74 CNR1 (0.45) ALDH1A1L3MBTL1ADRA1DADRA1AADRA1B
SCHEMBL3439989 0.72 L3MBTL1 (0.47) ALDH1A1L3MBTL1ADRA1DADRA1AADRA1B
SCHEMBL3507090 0.71 MEN1 (0.60) MEN1CYP1A2KMT2AALDH1A1KDM4E
SCHEMBL29161360 0.71 MEN1 (0.60) MEN1CYP1A2KMT2AALDH1A1KDM4E
SCHEMBL4994751 0.71 KDM4E (0.55) MEN1CYP1A2KMT2AALDH1A1KDM4E
SCHEMBL3194921 0.71 ALDH1A1 (0.52) MEN1KMT2AALDH1A1KDM4EHTR1A
SCHEMBL11553446 0.70 KDM4E (0.58) MEN1CYP1A2KMT2AALDH1A1KDM4E
Hydrochloric Acid SCHEMBL11313733 0.70 MEN1 (0.59) MEN1CYP1A2KMT2AALDH1A1KDM4E
SCHEMBL4994102 0.70 HTR2A (0.58) MEN1CYP1A2KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1871762-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2008-01-02 EP disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
WO-2006113704-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078135-A1 Substituted heteroaryl CB1 antagonists CNR1, CNR2, OPRL1 MEN1 3621/4885CYP1A2 808/4885KMT2A 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.